Clinical Research

RSS icon
To unpack the large number of lat-breaking trials at the American College of Cardiology 2026 meeting, Cardiovascular Business spoke in the above video interview with Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, director of the Mount Sinai Fuster Heart Hospital, who highlighted several studies he felt had the most scientific impact. This included a mix of drug, device and strategy trials pointing to advances in cardiology. #ACC #ACC26

Deepak Bhatt discusses some of the most impactful trials at ACC 2026

Bhatt describes a mix of drug, device and strategy trials pointing to advances in cardiovascular science.
 

Thumbnail

Screening and treatment for chronic kidney disease in heart disease patients needs to be expanded

The risk associated with under-recognized CKD emerged early, highlighting the need for screening soon after a CAD diagnosis so that cardio-renal protective drugs can be started much earlier.

brain stethoscope alzheimer's dementia

$13M federal grant fuels research into imaging AI for Alzheimer's

In total, NIH has awarded the project over $30 million. Researchers are hopeful that the funding will help pave the way for more personalized treatments for Alzheimer's. 

Kathryn Berlacher, MD, MS, FACC, chair of the 2026 American College of Cardiology (ACC) 2026 Scientific Sessions, and clinical director of cardiology and a women's heart and cardio-obstetrics specialist at the University of Pittsburgh Medical Center, explains the major trend of artificial intelligence (AI) in cardiology, the use of coronary CT angiography (CCTA) for the first time at a medical meeting to scan attendees, and the rise in hands on, guideline, business and advocacy sessions.

Impactful innovations reshape learning and technology at ACC.26

ACC.26 Chair Kathryn Berlacher, MD, MS, explained some of the big trends at this year's meeting, including AI, CCTA, hands-on training and guideline sessions.

prescription drugs

Cost-related medication non-adherence declined after the Inflation Reduction Act

Lower Medicare drug costs translated into more patients taking their medications, leading to better outcomes.

Former American College of Cardiology president Hadley Wilson, MD, FACC, executive vice chair of Atrium Health's Sanger Heart and Vascular Institute, shared his thoughts on what he saw as the key studies in the above video interview with Cardiovascular Business. He covered numerous trials in more detail in the video. #ACC26 #ACC

Key clinical takeaways from ACC.26

Hadley Wilson, MD, a former American College of Cardiology president, spoke to Cardiovascular Business about several studies presented at ACC.26.

Michiel Voskuil, MD, PhD, an interventional cardiologist and professor at University Medical Center Utrecht in the Netherlands, presented his team’s data on the ACC.26 stage.

PCI before TAVR? In older CAD patients, deferral may be the best approach

Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.

female patient speaking with a doctor

Premature menopause linked to substantial long-term heart risks

Starting menopause before the age of 40 could increase a woman's lifetime risk of coronary heart disease by up to 40%.

Displaying 57 - 64 of 1098
Design by Adaptive Theme